$TYL

TYLER TECHNOLOGIES INC (TYL): Results of Operations and Financial Condition

TYLER TECHNOLOGIES INC (TYL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a991earningsrelease-6302026.htm EX-99.1 Document Tyler Technologies Reports Earnings for Second Quarter 2026 and Announces New $1.5 Billion Share Repurchase Program • SaaS revenues grew 21.7% and SaaS bookings reached a new quarterly high • Expanded repurchase authoriza

Original reporting
Published Jul 29, 2026, 8:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$TYL
Bullish
high confidence
Mentioned
$TYL
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TYLBullishHigh
01

Why it matters

Traders can update models immediately using the disclosed Q2 operating metrics and the explicit 2026 guidance ranges, while also repricing capital return expectations from the new $1.5B repurchase authorization.

02

Market read

A primary-source earnings and guidance update with a fresh, sizable buyback authorization and quantified SaaS growth and free cash flow performance.

03

What to watch

Investors may focus on the gap between GAAP and non-GAAP profitability, the pace of SaaS bookings versus revenue, and how the For the Record acquisition and convertible notes affect future leverage and dilution dynamics.

Relevance 7/10Novelty 9/10Timing: after-hours following the Q2 2026 earnings release and ahead of the July 30, 2026 conference call

Background

The filing is an SEC 8-K (Item 2.02) attaching the company’s Q2 2026 results release and capital return updates.

Company-level read

Ticker impact

$TYLBullishHigh confidence
Context

Tyler reported Q2 results and full-year 2026 guidance, including SaaS revenue growth of 21.7% and free cash flow margin outlook of 26% to 28%.

Expected impact

Likely positive bias for TYl into the next trading session, with follow-through dependent on how investors weigh guidance versus buyback size and acquisition spend.

Evidence & confidence

The filing discloses multiple decision-relevant datapoints: Q2 revenue and FCF growth, explicit 2026 revenue, EPS, and FCF margin ranges, and a fresh $1.5B repurchase plan replacing prior authorizations.

Market effects

Reinforces demand durability for public-sector modernization and recurring SaaS monetization, a read-across positive for government software peers.

Primarily US-focused public sector software demand narrative.

Limited direct global impact; mostly US government modernization and software recurring revenue dynamics.

Counterpoint

Buyback and raised long-term targets may not offset near-term concerns about acquisition integration costs or the sustainability of transaction revenue growth.

Key entities

  • Tyler Technologies, Inc.

    Reported Q2 2026 results, provided full-year 2026 guidance, and announced a new $1.5B share repurchase authorization.

  • For the Record

    Acquired in April 2026 for about $212.7M cash, expanding Tyler’s justice portfolio with AI-powered transcription technology.

  • Convertible senior notes (2031)

    $1.4B offering in May 2026, with capped call transactions increasing the initial effective conversion price.

Related articles

$TYLMedAI 8/10

Tyler Technologies (TYL) Q2 2026 Earnings Call Transcript

Tyler Technologies (NYSE:TYL) reported Q2 2026 results on an earnings call. Management cited 21.7% YoY SaaS revenue growth, record free cash flow, and share repurchases exceeding 5.5% of shares outstanding YTD. It added $11M from acquisitions, including For The Record ARR of $1.6M and a $10M annual ARR digital motor vehicle titling deal. Full-year margin guidance called for about 100 bps expansion at the midpoint.

$TYLMed

Tyler Technologies Buys CODY Systems

Tyler Technologies said it has completed its acquisition of CODY Systems, a public safety software provider. The deal gives Tyler rights to CODY’s Pathfinder RMS cloud records management software and COBRAnet data-sharing platform. Tyler expects the purchase to expand its small to midsize public safety technology footprint and improve interoperability and real-time data access.

$TYLMed

Tyler Technologies Buys Public Safety Tech Firm CODY Systems

Tyler Technologies said it acquired Pennsylvania-based CODY Systems to expand public safety software. Tyler did not disclose the purchase price. CODY’s Pathfinder RMS and COBRAnet platforms will be integrated into Tyler products. CODY has 300+ clients in 10 states. Tyler reported Q2 revenue up 8.2% to $645.1 million and free cash flow up about 35% to $118.5 million.

$TYLMed

Why is Tyler Technologies stock sliding today?

Tyler Technologies (TYL) shares fell about 3% to $313.70 after its Q2 2026 results. Adjusted EPS was $3.08 vs $3.07 consensus, but revenue was $645.1 million vs about $648 million and adjusted EBITDA was $176.4 million vs $182.3 million. Piper Sandler cut its price target to $491 from $543.

$TYLMedAI 8/10

What Are Wall Street Analysts' Target Price for Tyler Technologies Stock?

Tyler Technologies (TYL) shares have underperformed the S&P 500 over the past year and in 2026, according to the article. After its Apr. 29 Q1 2026 results—revenue of $613.5M and adjusted EPS of $3.09, both above estimates—the company guided full-year revenue to $2.54B–$2.58B. Among 22 analysts, consensus is “Strong Buy”; targets range from $460 (D.A. Davidson) to $650, with a mean $442.40.

$LLYMedAI 8/10

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.